Korro Bio selects KRRO-111 as development candidate for alpha-1 antitrypsin deficiency treatment

Korro Bio advanced KRRO-111, a GalNAc-conjugated oligonucleotide, as a development candidate for alpha-1 antitrypsin deficiency, demonstrating >90% editing of SERPINA1 transcript in preclinical mouse models. The selection expands the company's pipeline alongside KRRO-121 and positions the therapy as a potential best-in-class treatment addressing a genetic disorder affecting an estimated 3.4 million individuals worldwide.